Serum peptides, represented by complement 3f des-arginine, are useful for prediction of the response to pegylated interferon-α plus ribavirin in patients with chronic hepatitis C

Hepatology Research

Volumn 43, Issue 7, 2013, Pages 743-756

  Noguchi, Yohei ^a,b   Kurokawa, Manae S ^a   Okuse, Chiaki ^b   Matsumoto, Nobuyuki ^b   Nagai, Kouhei ^a   Sato, Toshiyuki ^a   Arito, Mitsumi ^a   Suematsu, Naoya ^a   Okamoto, Kazuki ^a   Suzuki, Michihiro ^b,c   Itoh, Fumio ^b   Kato, Tomohiro ^a  

^a ST MARIANNA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KAWASAKI MUNICIPAL TAMA HOSPITAL   (Japan)

Author keywords

Biomarkers; Chronic hepatitis C; Complement 3f des arginine; Pegylated interferon plus ribavirin; Serum peptides

Indexed keywords

ARGININE DERIVATIVE; COMPLEMENT 3F DES ARGININE; INTERLEUKIN 28B; PEGINTERFERON ALPHA; PEPTIDE; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

EID: 84879711020     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12018     Document Type: Article

References (37)

1. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
2. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
3. McHutchison JG, Lawitz EJ, Shiffman ML etal. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
4. McHutchison JG, Manns MP, Muir AJ etal. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
5. Kwo PY, Lawitz EJ, McCone J etal. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
6. Morgan TR, O'Brien TR. IL28B-genotype testing now and in the era of direct-acting antiviral agents. Clin Gastroenterol Hepatol 2011; 9: 293-294.
7. Hadziyannis SJ, Sette H Jr, Morgan TR etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
8. Zeuzem S, Feinman SV, Rasenack J etal. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
9. Lindsay KL, Trepo C, Heintges T etal. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
10. McHutchison JG, Gordon SC, Schiff ER etal. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
11. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon- alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
13. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
14. Thompson AJ, Muir AJ, Sulkowski MS etal. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
15. Stättermayer AF, Stauber R, Hofer H etal. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-350.
16. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-867.
17. Ray S, Reddy PJ, Jain R etal. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011; 11: 2139-2161.
18. Paradis V, Asselah T, Dargere D etal. Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. Gastroenterology 2006; 130: 2189-2197.
19. Fujita N, Nakanishi M, Mukai J etal. Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis. Mol Med 2011; 17: 70-78.
20. Devitt EJ, Power KA, Lawless MW etal. Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin. Eur J Gastroenterol Hepatol 2011; 23: 177-183.
21. Patel K, Lucas JE, Thompson JW etal. High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. Hepatology 2011; 53: 1809-1818.
22. Tammen H, Peck A, Budde P etal. Peptidomics analysis of human blood specimens for biomarker discovery. Expert Rev Mol Diagn 2007; 7: 605-613.
23. Xiang Y, Matsui T, Matsuo K etal. Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells. Arthritis Rheum 2007; 56: 2018-2030.
24. Kaneshiro N, Xiang Y, Nagai K etal. Comprehensive analysis of short peptides in sera from patients with IgA nephropathy. Rapid Commun Mass Spectrom 2009; 23: 3720-3728.
25. Ikeda H, Suzuki M, Okuse C etal. Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response. Hepatol Res 2009; 39: 753-759.
26. Ichida F, Tsuji T, Omata M etal. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996; 6: 112-119.
27. Hatsugai M, Kurokawa MS, Kouro T etal. Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn's disease. J Gastroenterol 2010; 45: 488-500.
28. Asselah T, Bieche I, Narguet S etal. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 516-524.
29. O'Brien TR, Everhart JE, Morgan TR etal. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS ONE 2011; 6: e20904.
30. Ochi H, Hayes CN, Abe H etal. Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C. J Infect Dis 2012; 205: 204-210.
31. Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011; 26: 802-809.
32. Harrison RA, Lachmann PJ. Novel cleavage products of the third component of human complement. Mol Immunol 1980; 17: 219-228.
33. Ganu VS, Müller-Eberhard HJ, Hugli TE. Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized. Mol Immunol 1989; 26: 939-948.
34. Dill MT, Duong FH, Vogt JE etal. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031.
35. Perdomo AB, Ciccosanti F, Iacono OL etal. Liver protein profiling in chronic hepatitis C: identification of potential predictive markers for interferon therapy outcome. J Proteome Res 2012; 11: 717-727.
36. Ito K, Higami K, Masaki N etal. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol 2011; 49: 1853-1860.
37. Kobayashi M, Suzuki F, Akuta N etal. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1, 518 patients infected with hepatitis C virus. J Gastroenterol 2012; 47: 596-605.